Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin, M., Wang, J., Kleinberg, A., Kadalbajoo, M., Siu, K.W., Cooke, A., Bittner, M.A., Yao, Y., Thelemann, A., Ji, Q., Bhagwat, S., Mulvihill, K.M., Rechka, J.A., Pachter, J.A., Crew, A.P., Epstein, D., Mulvihill, M.J.(2013) Bioorg Med Chem Lett 23: 979-984
- PubMed: 23317569 
- DOI: https://doi.org/10.1016/j.bmcl.2012.12.042
- Primary Citation of Related Structures:  
4ID7 - PubMed Abstract: 
This Letter describes the medicinal chemistry effort towards a series of novel imidazo[1,5-a]pyrazine derived inhibitors of ACK1. Virtual screening led to the discovery of the initial hit, and subsequent exploration of structure-activity relationships and optimization of drug metabolism and pharmacokinetic properties led to the identification of potent, selective and orally bioavailable ACK1 inhibitors.
Organizational Affiliation: 
OSI Pharmaceuticals, LLC, A Wholly-Owned Subsidiary of Astellas US LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA. Meizhong.jin@astellas.com